Stockholders’ Equity and Warrants (Details Narrative)							2 Months Ended	3 Months Ended	12 Months Ended
Stockholders’ Equity and Warrants (Details Narrative)	Jun. 27, 2025 shares	Jun. 09, 2025 shares	Apr. 02, 2025 shares	Mar. 31, 2025 $ / shares shares	Oct. 29, 2024 USD ($) $ / shares shares	Sep. 24, 2024 USD ($) $ / shares shares	Dec. 24, 2024 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) $ / shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	May 01, 2025 USD ($)	Nov. 01, 2024 USD ($)
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price \| $ / shares									$ 0.075
Forward sales contract liability at fair value									$ 0
Outstanding common stock percentage			19.99%
Forward sales contract expense									5,847,000
Forward sales contract liability									$ 5,800,000
Common stock per share \| $ / shares									$ 0.005	$ 0.005
Convertible notes										$ 1,405,000
Number of shares converted \| shares					1,890,000
Loss on extinguishment of debt									765,000	(22,440,000)
Reclassification of warrants										11,244,000
Change in fair value of warrant liabilities									(1,000)	(414,000)
Additional paid-in capital						$ 600,000			247,997,000	233,219,000
Loss									(14,084,000)	(44,539,000)
Issuance of shares \| shares					2,553,000
Gross proceeds									$ 4,929,000	$ 1,137,000
Stock repurchased in period \| shares									0	0
Preferred stock, shares authorized \| shares									1,000,000	1,000,000
Preferred stock, shares issued \| shares									156,000	156,000
Preferred stock, shares outstanding \| shares									156,000	156,000
Series A Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares converted \| shares									0	0
Preferred stock, shares authorized \| shares									156,000
Preferred stock, shares issued \| shares									156,000
Preferred stock, shares outstanding \| shares									156,000
Cumulative annual dividend payable per share \| $ / shares									$ 0.10
Dividend paid in shares \| shares									7,000	1,000
Dividend paid in cash										$ 8,000
Preferred stock, liquidation preference per share \| $ / shares									$ 1.00
Preferred stock, conversion rate									32.3618
Each preferred stock converted into common stock \| shares									0.03
Aggregate preferred stock to be convert into common stock \| shares									5,000
Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Aggregate gross purchase price of shares												$ 1,000,000.0
Maximum [Member] \| Lincoln Park Capital Fund LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Aggregate gross purchase price of shares											$ 10,000,000.0
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of common stock issued \| shares	121,000	3,182,000	662,000						3,965,000
Reclassification of warrants
Loss
Issuance of shares \| shares							416,000
Principle amount							$ 3,000,000.0
Conversion price \| $ / shares							$ 7.50
Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price \| $ / shares							$ 0.075
warrants \| shares					1,327,000		118,000
Principle amount							$ 900,000
Conversion price \| $ / shares							$ 7.50
Issuance of shares \| shares					663,000
Convertible Debt [Member]
Subsidiary, Sale of Stock [Line Items]
Debt instrument interest rate stated percentage						10.00%
Forward Sales Contract [Member]
Subsidiary, Sale of Stock [Line Items]
Forward sales contract liability changes in fair value									$ 500,000
Pre Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of common stock issued \| shares		622,000	34,000						656,000
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price \| $ / shares									$ 411.74
Warrants outstanding weighted average contractual life									1 year 10 months 24 days
2025 Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Forward sales contract liability at fair value								$ 5,300,000
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding, weighted average exercise price \| $ / shares					$ 0.075
Issuance of shares \| shares					93,000
warrants \| shares					8,000
Gross proceeds					$ 1,100,000
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Discounted purchase price of shares and liability									$ 5,300,000
Forward sales contract liability at fair value									5,300,000
Loss on extinguishment of debt									21,900,000
Gain loss net tax on extinguishment of debt									600,000
Loss										22,400,000
Securities Purchase Agreement [Member] \| Pre Funded Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, price per share \| $ / shares				$ 1.494				$ 1.494
Warrants outstanding, weighted average exercise price \| $ / shares				$ 0.075				0.075
Securities Purchase Agreement [Member] \| Common Stock Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, price per share \| $ / shares						$ 11.175
Securities Purchase Agreement [Member] \| 2025 Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of common stock issued \| shares				4,621,000
Sale of stock, price per share \| $ / shares				$ 1.569				$ 1.569
Outstanding common stock percentage, description				4.99% or 9.99%
Securities Purchase Agreement [Member] \| Common Stock Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of common stock issued \| shares						101,000
Sale of stock, price per share \| $ / shares						$ 11.25
Exchange Agreements [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, price per share \| $ / shares						16.95
Common stock per share \| $ / shares						$ 0.50
Convertible notes						$ 28,400,000
Debt conversion \| $ / shares						$ 15.00
Convertible notes						$ 10,100,000
principal and accrued interest						19,400,000
Unamortized debt issuance costs						9,300,000
Fair value of reacquired convertible notes						$ 32,000,000.0
Number of shares converted \| shares						1,890,000
Loss on extinguishment of debt						$ 21,900,000				21,900,000
Income from change in fair value					$ 1,000,000.0
Reclassification of warrants						11,200,000
Change in fair value of warrant liabilities						$ 11,200,000			$ 300,000	$ 300,000
Exchange Agreements [Member] \| December 2022 Convertible Notes [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants purchase \| shares						9,000,000

Ernexa Therapeutics Inc. 10-K